Pfizer wins EU approval for MabThera biosimilar
The drug will be available to treat certain cancers and autoimmune conditions
Read More
Tag: Rituximab
Pfizer’s Rituxan biosimilar bags FDA approval
The treatment has been approved in adult patients with non-Hodgkin’s lymphoma.
Read More
Rituxan hits endpoints in late-stage skin disease trial
The drug demonstrated superiority to current standard-of-care to CellCept.
Read More
AZ, Forty Seven to test triple immunotherapy combo for lymphoma
5F9 will be tested in combination with rituximab and Calquence (acalabrutinib) for diffuse large B-cell lymphoma.
Read More
Rituximab found to extend progression-free survival in indolent lymphoma
New trial results have been published showing that a combination of Celgene’s Revlimid and Roche’s rituximab significantly extended progression-free survival in patients with relapsed or refractory indolent lymphoma, compared to rituximab with placebo.
Read More
Sandoz dumps US filing for biosimilar rituximab
Novartis group Sandoz has decided not to pursue US submission of a biosimilar version of Roche’s Rituxan/Mabthera, after a request from regulators for more data.
Read More
CTI, Servier’s Pixuvri fails in post-marketing trial
A late-stage trial of Servier and CTI BioPharma’s Pixuvri in combination with Roche’s MabThera has failed to hit targets in B-cell non-Hodgkin lymphoma, putting its conditional approval in Europe in jeopardy.
Read More
NHS England clears specialised treatments for NHS use
NHS England has approved routine funding for a stream of new specialised treatments, including stroke-reducing heart implants and a life changing surgical procedure for children with cerebral palsy.
Read More
AbbVie unveils high undetectable disease rates for venetoclax/rituximab combo
AbbVie has unveiled new data showing high and durable undetectable minimal residual disease rates in patients with chronic lymphocytic leukaemia treated with venetoclax in combination with rituximab.
Read More
US nod for Venclexta/Rituxan combo
US regulators have approved a combination of AbbVie and Roche’s Venclexta in combination with Roche/Biogen’s Rituxan (rituximab) to treat chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Read More
US widens scope of Rituxan to include life-threatening skin condition
Roche group Genentech has received US approval for Rituxan to treat moderate to severe pemphigus vulgaris (PV), giving patients access to the first new therapy for the condition in more than 60 years.
Read More
NEJM publishes venetoclax/rituximab data
A combination of venetoclax and rituximab being developed by AbbVie and Roche/Genentech significantly improved progression-free survival (PFS) in patients with chronic lymphocytic leukaemia (CLL), shows data published by the New England Journal of Medicine.
Read More
